Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.
Pintens
H
H
Beecham Pharmaceuticals, European Division, Brussels, Belgium.
D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D005289:Ferrets; D017829:Granisetron; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D002945:Cisplatin; D017829:Granisetron; D007191:Indazoles; D012702:Serotonin Antagonists